Drugs / SCM-010
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03696485 | Feb 2024 → Feb 2025 | secondary progressive multiple sclerosis | Stem Cell Medicine Ltd. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCM-010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03696485 ↗ |
| Modality | Cell therapy | “adipose derived expanded mesenchymal cells (ADSC)” NCT03696485 ↗ |
| Route | Intrathecal | “intended for intrathecal (IT) administration.” NCT03696485 ↗ |